News

Aug 22, 2024

Versant Ventures and Novartis Launch Borealis Biosciences With $150 Million in Funding

Jun 13, 2024

Santa Ana Bio Launches With $168 Million to Advance Precision Medicines for Inflammatory Diseases

Apr 20, 2023

Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer

Jan 04, 2023

Belharra Therapeutics Announces Broad Collaboration with Genentech to Discover and Develop Novel Medicines Across Multiple Therapeutic Areas

Jul 27, 2022

Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies

Apr 13, 2022

LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics

Sep 21, 2021

858 Therapeutics Launches with Proven Team and $60 Million Series A Financing

Sep 09, 2021

iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases

Sep 09, 2021

Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures

Aug 25, 2021

Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders

Aug 05, 2021

Versant Ventures Announces Acquisition of Portfolio Company Vividion Therapeutics

Jun 15, 2021

RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

Jun 15, 2021

CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia

Jun 10, 2021

Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors

Mar 03, 2021

Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline

Feb 24, 2021

Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs

Dec 08, 2020

RayzeBio Completes $105M Series B Financing to Advance Targeted Radiopharmaceuticals for Cancer

Oct 14, 2020

RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics

Aug 06, 2020

T-knife Completes €66 Million Series A Financing to Develop Next-Generation T-Cell Therapies

Mar 10, 2020

Versant Ventures Strengthens Global Team and Discovery Engine Infrastructure

Sep 04, 2019

Versant Ventures Enables Launch of Vensana Capital to Focus on Medtech Sector

Aug 22, 2019

Chinook Therapeutics Raises $65 Million Series A Financing to Advance Precision Medicines for Kidney Diseases

Aug 08, 2019

Versant Ventures Announces Acquisition of Cell Therapy Company BlueRock Therapeutics

Jul 01, 2019

Century Therapeutics Launches With USD 250M Financing for Induced Pluripotent Stem Cell (iPSC) Allogeneic Cell Therapy Platform

May 16, 2019

Tempest Therapeutics Starts Phase I/Ib Clinical Trial with First-in-Class PPAR Alpha Antagonist

Apr 30, 2019

Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing

Feb 14, 2019

Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases

Dec 12, 2018

Akero Therapeutics Announces $70 Million in New Financing to Advance Therapeutic Pipeline for NASH, Serious Metabolic Diseases

Nov 13, 2018

Tempest Therapeutics Reports Proof of Mechanism Data for First-in-Class PPAR Alpha Antagonist

Oct 31, 2018

Ophthotech Expands Innovative Retinal Disease Pipeline with Acquisition of Versant Ventures’ Inception 4

Sep 12, 2018

MPM Capital and Versant Ventures Launch CODA Biotherapeutics to Accelerate Development of Chemogenetic Gene Therapy Platform

Sep 11, 2018

Andrew Cheng, MD, PhD Joins Akero Therapeutics as President and Chief Executive Officer

Jun 25, 2018

Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases

May 23, 2018

Lava Therapeutics Raises EUR 16 Million to Advance Bispecific Gamma-Delta T Cell Engager Platform

Mar 05, 2018

Vividion Therapeutics Announces Strategic Research Collaboration with Celgene Corporation to Discover Therapies Against Transformative, First-in-Class Targets

Feb 27, 2018

Quentis Therapeutics Debuts with $48 Million Series A Financing to Advance First-in-Class Immunotherapies Targeting Endoplasmic Reticulum Stress Response Pathways

Jan 18, 2018

Pandion Therapeutics Announces $58 Million Series A Financing to Advance Tissue-Specific Immune Modulator Drugs for Autoimmune and Inflammatory Diseases

Nov 13, 2017

NousCom's Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in Preclinical Model

Sep 26, 2017

FierceBiotech Names Repare Therapeutics as One of Its “Fierce 15” Biotech Companies of 2017

Sep 26, 2017

FierceBiotech Names Gritstone Oncology as a "Fierce 15" Biotechnology Company of 2017

Jul 25, 2017

VenatoRx Pharmaceuticals Raises $42 Million Series B

Feb 28, 2017

CRISPR Therapeutics Announces the Appointment of Jon Terrett, Ph.D. to Head of Immuno-Oncology Research and Translation

Feb 15, 2017

Versant Ventures Launches Jecure Therapeutics

Feb 07, 2017

Flexion Therapeutics Announces New Drug Application for Zilretta™ (FX006) Accepted by U.S. Food and Drug Administration

Feb 02, 2017

Tarveda Therapeutics Raises $30 Million in Series D Financing to Advance Pentarin Miniaturized Drug Conjugates

Feb 02, 2017

Vividion Therapeutics, Inc., Launches With $50 Million Series A Financing

Dec 19, 2016

Versant Ventures Announces Milestone with Recent Northern Biologics and BlueRock Therapeutics Deals

Dec 19, 2016

Northern Biologics, Mosaic Biomedicals Execute Transformative Deal

Dec 12, 2016

Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing

Nov 02, 2016

Versant Ventures Portfolio Company Turnstone Biologics completes CAD$55.3 million Series B

Sep 26, 2016

Nouscom Appoints New Chief Operating Officer and Strengthens the Board of Directors

Nouscom, an oncology company developing patient specific cancer vaccines based on a clinically validated genetic vaccine platform, today announced the appointment of Dr Marina Udier Blagovic as Chief Operating Officer (COO).
Apr 12, 2016

Versant Ventures Strengthens Global Team

Announces Investment Team Promotions and Additions; New Discovery Engine Appointments

Media Contact

Steve Edelson
(415) 801-8088